Moving Beyond Viral Vectors for Gene Therapies

<p>Poseida Therapeutics is perhaps best known for its immune-oncology cell therapy products, but the company’s platform technologies are also being used to develop a growing pipeline of gene therapy candidates. While the most advanced ones in its pipeline use viral vectors, newer candidates make use of a non-viral nanoparticle vector. This technology can increase the payload of the gene therapy, avoid issues of immunogenicity, allow for redosing, and deliver manufacturing advantages. We spoke to Eric Ostertag, CEO of Poseida, about the company’s platform technology, its gene therapy pipeline, and its efforts to move beyond viral vectors. <em>Thanks to&nbsp;</em><a href="https://www.pfizer.com/" rel="noopener noreferrer" target="_blank"><em>Pfizer, Inc</em></a><em>.,&nbsp;</em><a href="https://www.bluebirdbio.com/" rel="noopener noreferrer" target="_blank"><em>Bluebird</em></a><em>, and&nbsp;</em><a href="https://www.novartis.com/our-company/novartis-pharmaceuticals/novartis-gene-therapies" rel="noopener noreferrer" target="_blank"><em>Novartis Gene Therapies</em></a><em>&nbsp;for their support of this podcast, part of our&nbsp;</em><a href="https://globalgenes.org/platforms-of-hope-advances-in-gene-therapy-and-gene-editing/" rel="noopener noreferrer" target="_blank"><em>Platforms of Hope: Advances in Gene Therapy and Gene Editing</em></a><em>&nbsp;series.</em></p>